Calls About Kratom To Poison Control Have Spiked 1,200% In The Past Decade

Why It Matters

The spike signals an emerging public‑health threat that could strain emergency services and amplify opioid‑type addiction risks, especially among youth. Without stronger regulation, kratom’s rapid market penetration may exacerbate substance‑use disorders nationwide.

Key Takeaways

• Kratom exposure calls rose 1,200% from 2015‑2025.
• 14,449 poison center reports and 538 hospitalizations in 2025.
• Teens face heightened risk from easy retail and online access.
• Federal regulation remains limited; only six states ban sales.
• Co‑use with alcohol or opioids doubles hospitalization rates.

Pulse Analysis

The CDC’s latest surveillance data places kratom on the radar of public‑health officials, showing an unprecedented 1,200% increase in poison‑control calls over a decade. While the absolute number of reports—14,449 exposures and 538 hospitalizations in 2025—remains modest compared with the opioid crisis, the upward trajectory mirrors a broader trend of novel psychoactive substances slipping through traditional monitoring systems. The rapid rise is fueled by the herb’s dual pharmacology: low doses act as stimulants, while higher doses produce opioid‑like sedation, creating a confusing risk profile for users and clinicians alike.

Regulatory responses remain fragmented. Six states—Alabama, Arkansas, Indiana, Louisiana, Vermont, and Wisconsin—have outright bans, and 23 others impose licensing or age‑restriction rules. The FDA’s recent move to place the potent 7‑OH kratom derivative on the controlled‑substances list marks the first federal step toward tighter control, yet the bulk of the market continues to thrive in gas stations, smoke shops, and e‑commerce platforms. This patchwork of rules hampers consistent enforcement and leaves consumers, especially teenagers, vulnerable to unverified products and misleading marketing.

For parents, educators, and healthcare providers, the data underscore a need for proactive outreach. Early conversations about the deceptive safety narrative surrounding “herbal” supplements can mitigate experimentation. Clinicians should screen for kratom use when assessing unexplained liver injury, seizures, or respiratory depression, particularly in poly‑substance contexts. Policymakers may consider harmonizing state regulations and accelerating federal scheduling to curb easy access, thereby reducing the looming burden on emergency services and addiction treatment systems.